LIGANDROL (LGD-4033) Powder, 1gr
LIGANDROL (LGD-4033) Powder, 1gr
Couldn't load pickup availability
LIGANDROL (LGD-4033)
LGD 4033, also known as Ligandrol, VK5211, or Anabolicum, is a Selective Androgen Receptor Modulator (SARM). Various animal studies have demonstrated that it increases anabolic activity in muscles. It has also shown positive effects on bone density in male rats suffering from hypogonadism and has been successful in treating female postmenopausal rats experiencing osteoporosis.
LGD 4033: Effects on Bones and Muscles
Research presented at the 62nd Annual Meeting of the Gerontology Society of America revealed that the use of LGD 4033 in animals increased both resistance to fractures and bone mineral density after 12 weeks. These effects were observed in porous bone at a dose of 0.3 mg/kg per day and in cortical bone at a dose of 0.03 mg/kg per day (source).
In both hypogonadal and normal rats, LGD 4033 increased skeletal muscle mass and the diameter of muscle fibers. This correlated with an increased contractile strength of the muscles, indicating improved muscle power.
In an intriguing study conducted by Roche et al., 3-month-old Sprague-Dawley rats underwent ovariectomy and were treated with LGD 4033 for 5 weeks. Rats in the experimental groups received doses ranging from 0.04 to 4 mg/kg of body weight per day. Subsequent analyses were performed on fiber size, capillary density, and various enzyme levels. Additionally, the weights of the uterus, gastrocnemius, and soleus muscles were measured before and after treatment (source).
In analyzing the effects of LGD 4033, researchers also took samples from the quadriceps femoris muscle to measure changes in intramuscular fat content. Treatment with LGD 4033 resulted in an increased capillary density and higher enzymatic activity of both citrate synthase in the gastrocnemius muscle and lactate dehydrogenase in the longissimus muscle (source).
Half Life
24 – 36 hours.
DISCLAIMER
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or domestic use. Please familiarize yourself with our DISCLAIMER before ordering.
Data Sheet
LGD-4033 – Powder, 1gr
| Application | Selective Androgen Receptor Modulator |
| CAS | 1165910-22-4 |
| Molar Mass | 338.25 g/mol |
| Chemical Formula | C14H12F6N2O |
| IUPAC Name | 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile |
| Synonyms | LG4, LG-4, 1165910-22-4, UNII-1EJT54415A, 4-((R)-2-((R)-2,2,2-Trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-(trifluoromethyl)benzonitrile, 1EJT54415A, 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)benzonitrile, 4-{(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl}-2-(trifluoromethyl)benzonitrile, SCHEMBL221159, DTXSID10657620, EX-A729, PUBCHEM_44137686, BCP07128, s8822, ZINC95830588, AKOS022173564, CS-4667, DB13934, AC-30218, AK141891, HY-13981, AX8259791, A14346, J-690039, Q21098841, 4-[(2R)-2-[(1R)-2,2,2-TRIFLUORO-1-HYDROXYETHYL]PYRROLIDIN-1-YL]-2-(TRIFLUOROMETHYL)BENZONITRILE, Benzonitrile, 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)- |
| Storage | Room temperature |
| Solubility | Soluble in Ethanol, PEG400, PG, Glycerin |
| Organoleptic Profile | White fine powder |
| Physical Form | Solid |
| Specification | ≥98% |
| Terms | This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering. |
